Manav Sadhwani
manav84
225Ac-PSMA-617 – A New Beginning in the Treatment of Prostate Cancer
The 225ac labeled derivative – 225Ac-PSMA-617, has shown remarkable therapeutic efficacy, especially in metastatic castrate-resistant prostate cancer (mcrpc) patients. More details available at nuclearmedicinetherapy.in/blog/225ac-psma-617-a-new-begin...
123
views
0
faves
0
comments
Uploaded on July 16, 2020
225Ac-PSMA-617 – A New Beginning in the Treatment of Prostate Cancer
The 225ac labeled derivative – 225Ac-PSMA-617, has shown remarkable therapeutic efficacy, especially in metastatic castrate-resistant prostate cancer (mcrpc) patients. More details available at nuclearmedicinetherapy.in/blog/225ac-psma-617-a-new-begin...
123
views
0
faves
0
comments
Uploaded on July 16, 2020